Mokhoa oa Immunological: Mokhoa oa ho ba le ts'oaetso Alleles e Skew Sehlopha sa MHC sa I Ligandome
Boemong ba limolek'hule, ramatiki ea psoriatic e hokahane haholo le li-alleles tse ikhethang tsa HLA Class I, haholo-holo HLA-C06:02, HLA-B27, HLA-B13, le HLA-B57. Patlisiso ka lithuto tsa peptide tse tlamang cleft polymorphism (2020) e bonts'a hore ho ba le ts'oaetso ho PsA ho susumetsoa haholo ke likarolo tsa sebopeho se arolelanoang ho pholletsa le HLA peptide-binding groove-haholo-holo mokhoa o ikhethileng oa tefiso e mpe ka pokothong ea B le masalla a polymorphic maemong. 97.
Moralo ona oa meralo o fetola khetho e tlamang ea molek'hule ea MHC Class I.. Ho ena le ho bonahatsa bophara, homeostatic cross-section ea cellular proteome, susceptibility allotypes ka boikhethelo e ruisa li-peptide tse nang le masalla a mantlha, joalo ka arginine boemong 2 (P2) kapa boemo 3 (P3). Ha e kopantsoe le mefuta e fapaneng e amanang le lefu la antigen-processing aminopeptidase (ERAP1 le ERAP2), joalo ka ha ho totobalitsoe ho Tumellano ea EULAR mabapi le MHC-I-opathies (2023), mochini oa sele o etsang li-antigen o hlahisa peptidome e khelohileng.
|
Ntho |
Lintlha |
|---|---|
|
Tlhōlisano e Tloaelehileng |
Diverse Homeostatic Proteome → E sa Skewed HLA-I Ligandome → Mamello ea 'mele |
|
Boemo ba lefu la PsA |
Ts'oaetso ea HLA Allotypes + Mefuta e meng ea ERAP → Skewed P2/P3 Arginine-Rich Ligandome → Autoreactive CD8+ T Cell Activation |
Sebakeng sa lisele tsa synovial le libaka tsa entheseal, leeme lena la tlhahiso le fella ka boemeli bo feteletseng ba li-peptide tse khethehileng tsa autoantigenic-joalo ka likhechana tse nkiloeng ho liprotheine tse amanang le melanocyte joalo ka ADAMTSL5 kapa liprotheine tsa matrix tse ikhethileng ka lefufuru.. Li-peptide tsena tse hlahisoang ho feta tekano li kenya lisele tsa CD8+ T tsa autoreactive, ho tsosa li-cascade tse ruruhileng sebakeng sa heno le ho senyeha ha lisele.
Bakeng sa bafuputsi ba biopharma, ho lekanya liphetoho tsena tse poteletseng tsa tlhahiso-hangata tse kenyelletsang liphetoho tse nyane tsa tlhahiso ea peptide ea boemo ba femtomole-ke ea bohlokoa ho netefatsa hore na phekolo ea mokhethoa e atlehile ho tsosolosa tekanyo e tloaelehileng ea ligandome kapa ka ho khetha e hatella pontšo ea peptide ea pathogenic..
Hobaneng ha Discovery Proteomics e sa Reroang e hloleha ho lekanya Liphetoho tsa Phatlalatso
Ho lekanya tlhahiso ea HLA Class I, liphuputso tsa mohato oa pele li itšetlehile haholo ka Phano ea Data-Dependent e sa rereloang (DDA) chromatography ea metsi - tandem mass spectrometry (LC-MS/MS). Leha DDA e le ea bohlokoa bakeng sa 'mapa oa boleng ba pele, e bonts'a mefokolo e matla ea sebopeho ha e sebelisoa lithutong tse ngata tsa phetolelo:
-
Mehlala ea Stochastic le Litefiso tse Felletseng tsa Boleng: Ka DDA, spectrometer ea boima e khetha li-ion tse matla ka ho fetisisa bakeng sa ho arola potolohong e 'ngoe le e' ngoe ea mosebetsi.. Hobane li-peptide tsa HLA Class I ka tlhaho ha li tryptic, bolelele bo fapaneng haholo (ka tlwaelo 8 ho 11 li-amino acid), 'me e hlahisoa ka bongata bo tlase haholo (femtomoles ka milligram ea linama kapa likopi ka sele), li-peptide tse ngata tse tlase tsa pathogenic hangata li hloloheloa lihlopheng tsa bongaka, ho fana ka litekanyetso tse sieo tsa boleng ba 40% ho 60%.
-
Ho haella ha Liankora tse Felletseng: Matla a tlhoro ea DDA ha a tsamaellane hantle le linomoro tsa kopi tsa bokaholimo ba lisele. Ntle le litekanyetso tsa isotopic tse tsamaellanang, liphetoho tse poteletseng tsa polelo (mohlala, keketseho ea makhetlo a 2.5 ho peptide ea autoantigenic) e ka se khethollehe ho feto-fetoha ha ionization e bakoang ke matrix kapa tahlehelo ea ho sebetsana le mehlala.
-
Lintho tse entsoeng ka matsoho tse tsoang ho li-Peptide tse Tloaelehileng tsa Substandard: Ho netefatsa ho otla ha immunopeptidomic ho hloka litšupiso tsa maiketsetso tsa peptide. Leha ho le joalo, li-peptide tsa maiketsetso tse tloaelehileng tsa boemo ba thuto (70% ho 80% bohloeki) jara litšila tse kholo tsa lik'hemik'hale. Trifluoroacetate e setseng (TFA) li-counter-ion li baka ionization e matla ea electrospray (ESI) quenching, ha lihlahisoa tse sa phethahalang tsa ts'ireletso li theha matšoao a pele a fosahetseng a khopamisang ho nepahala ha palo..
Key Takeaway: Li-proteomics tsa DDA tse sa reroang li loketse ho sibolloa ha ligand qalong, empa netefatso ea sepheo sa phetolelo e hloka liteko tse lebisitsoeng tsa LC-MS/MS tse tšehelitsoeng ke li-peptide tsa maiketsetso tsa tloaelo tse hloekileng le litekanyetso tse boima tsa isotopic..
The Strategic Imperative: Ts'ebetso e kopaneng ea Immunopeptidomics
Ho fihlela ho tiea ha tlhahlobo e hlokahalang bakeng sa netefatso ea sepheo sa IND, lihlopha tsa lipatlisiso tsa bafetoleli li fetohela mekhoeng e lebisitsoeng ea LC-MS/MS—e kang Selected Reaction Monitoring. (SRM), Parallel Reaction Monitoring (PRM), le Internal Standard-Triggered PRM (KE-PRM). Ho kenya tšebetsong litlhahlobo tsena tse tsoetseng pele ka katleho ho hloka mokhoa o kopaneng oa litšiea tse tharo.
|
Pilara ea Mosebetsi |
Karolo ea Theknoloji |
Karolo ea Leano ho Immunopeptidomics |
|---|---|---|
|
Lipilisi 1: Liphanele tse ikhethileng tsa Peptide |
Boemo bo phahameng, lilaebrari tsa peptide tse tsebahalang ka botlalo |
E fana ka litšupiso tsa mabone a maiketsetso a tsamaellanang le li-ligand tsa HLA tse boletsoeng esale pele kapa tse sibollotsoeng bakeng sa ho lekanya nako ea ho boloka le moaho oa laeborari ea MS/MS spectral.. |
|
Lipilisi 2: SIL Litekanyetso tse boima |
Li-peptide tse nang le li-isotope tse tsitsitseng tse kenyelletsang ^{13}C₆, ^{15}N₄ Arg kapa ^{13}C₆, ^{15}N₂ Lenane |
E sebetsa joalo ka li-ankora tsa ka hare tsa co-eluting, ho etsa hore tekanyo e nepahetseng ea phetolo-phetoho le quantification e felletseng ea lisele. |
|
Peptide Synthesis Lipilisi 3: Tšehetso ea ntlafatso ea liteko |
Ntlafatso ea fensetere ea ho itšehla thajana, net peptide content calibration, phapanyetsano ea counter-ion |
E thibela tšitiso ea boima ba isobaric, e felisa khatello ea ion ea TFA, hape e netefatsa ho ikatisa ha tlhahlobo ea batch-to-batch. |
1. Liphanele tsa Peptide tse Lebeletsoeng
Phetolelo ea immunomics e qala ka liphanele tse entsoeng ka tloaelo tse tsamaellanang le peptidome e amanang le lefu.. Bakeng sa lipatlisiso tsa PsA, liphanele li tlameha ho koahela HLA-C e khethehileng06:02 le HLA-B27 tlamang motifs. Ho sebelisa sethala se ikhethileng joalo ka Mokhoa o Tloaelehileng oa Peptide Synthesis e netefatsa hore li-peptide tsa maiketsetso li hlahisoa ka tatellano e tiisitsoeng ea botšepehi, litaolo tse thata tsa bolelele, le bohloeki bo phahameng (≥ 95%), ho fana ka lilaebrari tse tšepahalang tsa spectral bakeng sa ho fumana LC-MS/MS.
2. Isotope e tsitsitseng-E ngotsoe (SILE) Melao ea ka Hare
Ho lekanya tlhahiso ho fetoha ka matla, li-peptide tse boima tsa maiketsetso li kenngoa ka har'a sampole ea HLA ligand e sa sebetseng pele ho tlhahlobo ea LC-MS/MS.. Ka ho kenyelletsa li-isotopi tse boima tse tsitsitseng (^{13}C le ^{15}N) ho kena mesaletsa ea mantlha ea C-terminal (joalo ka Heavy Arginine [+10 Le] kapa Heavy Lysine [+8 Le]), maemo a boima a bonts'a nako e ts'oanang ea ho boloka chromatographic, katleho ea ionization, le boits'oaro ba ho arohana joalo ka endogenous light ligand.
Joalokaha ho hlalositsoe ka botlalo lipatlisisong tsa e lebisitsoeng ho IS-PRM immunopeptidomics workflows (2024), leveraging Isotope e bitsoang Peptides e lumella li-spectrometer tse ngata ho etsa hore ho fihleloe sepheo, ho felisa litlamorao tsa matrix le ho nolofalletsa quantification e ka hlahisoang ho fihla maemong a single-attomole.
3. Ntlafatso ea Assay e inehetseng & Tšehetso ea boleng
Litekanyetso tsa boleng bo holimo tsa SIL feela ha li lekane haeba lintlha tsa k'hemistri ea 'mele li hlokomolohuoa:
-
Netefatso ea Net Peptide Content: Boima ba peptide ea maiketsetso bo na le peptide e hloekileng le metsi a tlamiloeng kapa li-counter-ion. Ntle le boikemisetso bo nepahetseng ba litaba tsa peptide (ka tlhahlobo ea amino acid kapa qeto ea naetrojene), absolute quantitative calculations jara liphoso tsa ho fihlela ho 30%.
-
TFA-to-Acetate Counter-Ion Exchange: Sebopeho se tloaelehileng sa peptide e tsitsitseng e siea TFA e setseng, sesebelisoa se matla sa ion-pairing se timang matšoao a electrospray ho nanoLC-MS. Ho etsa phapanyetsano ea li-counter-ion ho letsoai la acetate kapa la hydrochloride ho khutlisa kutloisiso ea MS.
-
Precursor Window Overlap Planning: Ho rala liphanele tsa SIL tse lebisitsoeng ho hloka lipalo tse hlokolosi tsa m/z ho netefatsa hore litekanyetso tse boima ha li oele ka har'a fensetere ea ho itšehla thajana. (hangata ±1 m/z) ya bahlahlobi ba diphanele tse ding kapa ditshila tse sa ngolwang.
Bakeng sa Keletso: Kamehla netefatsa lintlha tsa counter-ion le net peptide content pele u phahamisa litekanyetso tsa SIL ho lisampole tsa bohlokoa tsa kliniki tse immunopurified.. Ho hlahloba tataiso e felletseng ka Li-Peptide tsa Synthetic rel="latela" class="link" href="https://molchanges.com/beyond-the-coa-third-party-peptide-testing-audit-guide.html”>Teko ea Peptide le Netefatso ea Boleng li thusa ho netefatsa botsitso ba tlhahlobo ea batch-to-batch.
Ho Potlakisa Tiiso ea Biomarker le Nts'etsopele ea Safer Biologics
Ho amohela mofuta o kopaneng oa ts'ebeletso ea immunopeptidomics ho hlahisa melemo e tobileng ea khoebo le saense bakeng sa biopharma R.&D lihlopha:
-
Netefatso e matla ea Biomarker: Lihlopha tsa bafetoleli li ka beha leihlo matšoao a khethehileng ho lihlopha tsa bakuli ba nako e telele, ho theha litekanyo tse ngata bakeng sa ts'ebetso ea mafu, karabo ea phekolo, kapa ho khutlela mokhoeng oa ramatiki oa psoriatic. Tlhahiso ea Peptide
-
De-Risking TCR-Like Biologics le Peptide-HLA Therapeutics: Li-biologics tse etselitsoeng ho shebana le mefuta e itseng ea peptide-MHC (mohlala, Li-antibodies tse kang TCR kapa li-bispecific T-cell tse kenyang letsoho) hloka bopaki bo felletseng ba boitlamo ba tlhahiso. Palo e reriloeng e thehiloeng ho SIL e theha palo e nepahetseng ea kopi ea cell-surface e hlokahalang bakeng sa katleho ea kalafo..
-
Tšireletseho e sa Lebeletsoeng le Tlhahlobo ea Cross-Reactivity: Ka ho lekanya tlhahiso ea mantlha ho li-tissue tse phetseng hantle tse sa lebelloang, bahlahisi ba biopharma ba ka lekola ts'ebetso e ka bang teng ntle le sepheo pele ho nts'etsopele ea pele, ho qoba chefo e kotsi ea autoimmune litekong tsa bongaka.
Ho sebelisana le Lipolanete tse Khethehileng tsa Peptide bakeng sa Katleho ea Phetolelo
Ho leka-lekanya tlhahiso ea peptide ea Sehlopha sa I ea MHC ho psoriatic ramatiki e hloka kopanyo e se nang moeli pakeng tsa chemistry ea peptide le quantitative mass spectrometry.. Barekisi ba lethathamo la lihlahisoa tse tloaelehileng hangata ha ba na litaolo tse khethehileng tsa boleng-joalo ka Sehlopha 100 ultra-sterile synthesis tikoloho, litaba tsa peptide tse netefalitsoeng, le phetoho ea TFA-to-acetate-e hlokehang bakeng sa immunopeptidomics e tsoetseng pele.
Ka ho sebelisa chelete Litšebeletso tse Pharalletseng tsa Peptide ho tsoa ho R&D balekane ba rata MOL Liphetoho, baetsi ba liqeto tsa biopharma ba fumana phihlello e tobileng ea moralo oa tatellano ea moetlo, boleng bo phahameng ba SIL e tloaelehileng ea synthesis, fedile 300 liphetoho tse sebetsang, le tšehetso ea nts'etsopele ea tlhahlobo ea mahlale ho isa ho mahlale.
Hore na sehlopha sa hau se netefatsa lipheo tse ncha tsa autoimmune, ho khetholla li-immunopeptidome tse khethehileng tsa lefu, kapa ho hlahloba li-lead biologics bakeng sa ts'ebetso e fapaneng ea sepheo, peptide e kopaneng ea tloaelo le ts'ebetso e tloaelehileng ea SIL e fana ka lintlha tse hlakileng tse hlokahalang ho ntšetsa pele polokeho, liphekolo tse sebetsang hantle haholo tleliniking.
